Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Hepatocellular Carcinoma: The Current Recommendations for Clinical Practice
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Hepatocellular Carcinoma: The Current Recommendations for Clinical Practice

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: closed (28 February 2021) | Viewed by 17095

Special Issue Editors

Dr. Miroslaw Kornek

E-Mail Website
Guest Editor
Department of Internal Medicine I, University Medical Center Bonn, Bonn, Germany
Interests: liver cancer; HCC; CCA; hepatobiliary cancer; extracellular vesicles; liquid biopsy
Special Issues, Collections and Topics in MDPI journals
Dr. Tudor Mocan

E-Mail Website
Guest Editor
Institute for Gastroenterology and Hepatology "O.Fodor", University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania
Interests: liver cancer; liver biopsy; immunotherapy
Prof. Dr. Zeno Spârchez

E-Mail
Guest Editor
Institute of Gastroenterology and Hepatology, "Prof. Dr. Octavian Fodor", University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania
Interests: liver cancer; thermal ablation; minimal invasive therapies; interventional ultrasound; liver cirrhosis; pancreatistis; biliary cancers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to announce an upcoming Special Issue of JCM entitled “Hepatocellular Carcinoma: The Current Recommendations for Clinical Practice”. In recent decades, significant improvments in the management of chronic liver diseases, cirrohosis and hepatocellular carcinoma (HCC) have occurred. Notably, treatment has moved from interferon-based to interferon-free regimens, from liver biopsy to liquid biopsy, from percutaneous ethanol injection to percutaneous radiofrequency or microwave ablation, and from tyrosine kinase inhibitors to immunotherapies. However, HCC, the most common liver malignancy worldwide, still remains a major cause of cancer-related mortality. This Special Issue aims to cover the most relevant information on both preclinical (mainly translational studies with possible clinical applications) and clinical areas ranging from new diagnosis or prognostic biomarkers to novel treatment options. Special consideration will be given to papers covering hot topics including differential diagnosis between HCC and other focal liver lesions in patients with cirrhosis, clinical application of liquid biopsis for the diagnosis or prognosis of patients with HCC, novel immunotherapy strategies, and the importance of HCC variants and tumor heterogeneity in clinical practice.

Dr. Miroslaw Kornek
Dr. Tudor Mocan
Dr. Zeno Spârchez
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Liver
  • HCC
  • Heptobiliary carcinoma
  • Minimal invasive
  • Liquid biopsy
  • Ablation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

8 pages, 1433 KiB  
Article
Is There a Place for Elastography in the Diagnosis of Hepatocellular Carcinoma?
by Ana-Maria Ghiuchici, Ioan Sporea, Mirela Dănilă, Roxana Șirli, Tudor Moga, Felix Bende and Alina Popescu
J. Clin. Med. 2021, 10(8), 1710; https://doi.org/10.3390/jcm10081710 - 15 Apr 2021
Cited by 3 | Viewed by 2736
Abstract
Background and Aims: Elastography can provide information regarding tissue stiffness (TS). This study aimed to analyze the elastographic features of hepatocellular carcinoma (HCC) and the factors that influence intratumoral elastographic variability in patients with liver cirrhosis. Methods: This prospective study included 115 patients [...] Read more.
Background and Aims: Elastography can provide information regarding tissue stiffness (TS). This study aimed to analyze the elastographic features of hepatocellular carcinoma (HCC) and the factors that influence intratumoral elastographic variability in patients with liver cirrhosis. Methods: This prospective study included 115 patients with liver cirrhosis and hepatocellular carcinoma evaluated between June 2016–November 2019. A total of 88 HCC nodules visualized in conventional abdominal ultrasound (US) met the inclusion criteria and underwent elastographic evaluation. Elastographic measurements (EM) were performed in HCC and liver parenchyma using VTQ (Virtual Touch Quantification), a point shear wave elastography (pSWE) technique. In all patients, we performed contrast-enhanced ultrasound (CEUS), and the final diagnosis of HCC was established by contrast-enhanced-CT or contrast-enhanced-MRI. Results: The mean VTQ values in HCCs were 2.16 ± 0.75 m/s. TS was significantly lower in HCCs than in the surrounding liver parenchyma 2.16 ± 0.75 m/s vs. 2.78 ± 0.92 (p < 0.001). We did not find significant differences between the first five and the last five EM, and the intra-observer reproducibility was excellent ICC: 0.902 (95% CI: 0.87–0.950). However, the tumor size, heterogeneity, and depth correlated with higher intralesional stiffness variability (p < 0.001). Conclusions: VTQ brings additional information for HCC characterization. Intra-observer reproducibility for both HCC and liver parenchyma was excellent. Knowing the stiffness of HCC’s might endorse an algorithm-based approach towards focal liver lesions (FLLs) in liver cirrhosis. Full article
(This article belongs to the Special Issue Hepatocellular Carcinoma: The Current Recommendations for Clinical Practice)
►▼ Show Figures

Figure 1

12 pages, 1012 KiB  
Article
A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
by Jaejun Lee, Pil Soo Sung, Hyun Yang, Soon Kyu Lee, Hee Chul Nam, Sun Hong Yoo, Hae Lim Lee, Hee Yeon Kim, Sung Won Lee, Jung Hyun Kwon, Jeong Won Jang, Chang Wook Kim, Soon Woo Nam, Si Hyun Bae, Jong Young Choi and Seung Kew Yoon
J. Clin. Med. 2020, 9(12), 4121; https://doi.org/10.3390/jcm9124121 - 21 Dec 2020
Cited by 29 | Viewed by 3296
Abstract
Background/Aims: Lenvatinib was recently approved as a first-line oral multikinase inhibitor for unresectable hepatocellular carcinoma (HCC). In this study, we aimed to compare the efficacy and safety of lenvatinib and sorafenib for the treatment of unresectable HCC in patients with prior failure of [...] Read more.
Background/Aims: Lenvatinib was recently approved as a first-line oral multikinase inhibitor for unresectable hepatocellular carcinoma (HCC). In this study, we aimed to compare the efficacy and safety of lenvatinib and sorafenib for the treatment of unresectable HCC in patients with prior failure of transarterial treatment. Methods: Between January 2019 and September 2020, 98 unresectable HCC patients treated with lenvatinib or sorafenib as salvage therapy were enrolled from five Korean university-affiliated hospitals. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and disease control rate were calculated to assess the antitumor response. Results: A total of 43 and 55 patients were treated with lenvatinib and sorafenib, respectively, as salvage therapy after the failure of transarterial treatments. The median PFS was 4.97 months in the lenvatinib group and 2.47 months in the sorafenib group (p = 0.001, log-rank test). The ORR was significantly higher in the lenvatinib group (25.6%) than in the sorafenib group (3.6%, p = 0.002). Use of lenvatinib over sorafenib (hazard ratio: 0.359, 95% confidence interval: 0.203–0.635, p < 0.001) was the most significant factor for a favorable PFS after the failure of transarterial treatments in all enrolled patients. For favorable OS, achieving objective response was the significant factor (hazard ratio 0.356, 95% confidence interval: 0.132–0.957, p = 0.041). There were no significant differences in the safety profile between the two groups. Conclusions: In this real-world study, lenvatinib was demonstrated to be more efficacious than sorafenib as a salvage therapy for transarterial treatments in unresectable HCC. Full article
(This article belongs to the Special Issue Hepatocellular Carcinoma: The Current Recommendations for Clinical Practice)
►▼ Show Figures

Figure 1

Review

Jump to: Research

20 pages, 1481 KiB  
Review
Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward?
by Zeno Sparchez, Rares Craciun, Cosmin Caraiani, Adelina Horhat, Iuliana Nenu, Bogdan Procopet, Mihaela Sparchez, Horia Stefanescu and Tudor Mocan
J. Clin. Med. 2021, 10(5), 903; https://doi.org/10.3390/jcm10050903 - 25 Feb 2021
Cited by 12 | Viewed by 5167
Abstract
Hepatocellular carcinoma (HCC) is probably the epitome of a screening target, with a well-defined high-risk population, accessible screening methods, and multiple curative-intent treatments available for early disease. Per major societies guideline consensus, biannual ultrasound (US) surveillance of the at-risk patients is the current [...] Read more.
Hepatocellular carcinoma (HCC) is probably the epitome of a screening target, with a well-defined high-risk population, accessible screening methods, and multiple curative-intent treatments available for early disease. Per major societies guideline consensus, biannual ultrasound (US) surveillance of the at-risk patients is the current standard of care worldwide. Yet, despite its documented success in the past decades, this standard is far from perfect. While the whole community is working to further tighten the knots, a worrying number of cases still slip through this safety net. Consequently, these patients lose their chance to a curative solution which leads to a high disease burden with disproportionate mortality. While US will probably remain the fundamental staple in the screening strategy, key questions are seeking better answers. How can its caveats be addressed, and the technique be improved? When are further steps needed? How to increase accuracy without giving up on accessibility? This narrative review discusses the place of US surveillance in the bigger HCC picture, trying to navigate through its strengths and limits based on the most recent available evidence. Full article
(This article belongs to the Special Issue Hepatocellular Carcinoma: The Current Recommendations for Clinical Practice)
►▼ Show Figures

Figure 1

26 pages, 890 KiB  
Review
Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?
by Tudor Mocan, André L. Simão, Rui E. Castro, Cecília M. P. Rodrigues, Artur Słomka, Bingduo Wang, Christian Strassburg, Aliona Wöhler, Arnulf G. Willms and Miroslaw Kornek
J. Clin. Med. 2020, 9(5), 1541; https://doi.org/10.3390/jcm9051541 - 20 May 2020
Cited by 39 | Viewed by 4974
Abstract
Hepatocellular carcinoma (HCC) represents the sixth most common cancer worldwide and the third most common cause of cancer-related death. One of the major problems faced by researchers and clinicians in this area is the lack of reliable disease biomarkers, which would allow for [...] Read more.
Hepatocellular carcinoma (HCC) represents the sixth most common cancer worldwide and the third most common cause of cancer-related death. One of the major problems faced by researchers and clinicians in this area is the lack of reliable disease biomarkers, which would allow for an earlier diagnosis, follow-up or prediction of treatment response, among others. In this regard, the “HCC circulome”, defined as the pool of circulating molecules in the bloodstream derived from the primary tumor, represents an appealing target, the so called liquid biopsy. Such molecules encompass circulating tumor proteins, circulating tumor cells (CTCs), extracellular vesicles (EVs), tumor-educated platelets (TEPs), and circulating tumor nucleic acids, namely circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA). In this article, we summarize recent findings highlighting the promising role of liquid biopsies as novel potential biomarkers in HCC, emphasizing on its clinical performance. Full article
(This article belongs to the Special Issue Hepatocellular Carcinoma: The Current Recommendations for Clinical Practice)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop